Bicycle therapeutics announces pricing of $200 million public offering of american depositary shares and non-voting ordinary shares

Cambridge, england & boston--(business wire)--bicycle therapeutics plc (nasdaq: bcyc), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today announced the pricing of an underwritten public offering of 9,411,766 american depositary shares (“adss”), each representing one ordinary share and, in lieu of adss to investors that so choose, non-voting ordinary shares, each at a price to the public of $21.
BCYC Ratings Summary
BCYC Quant Ranking